- GSK will relocate its UK R&D operations from Stevenage to a new flagship campus in Cambridge.
- The move is part of a three-year plan targeting £1.9 billion in annual cost savings by 2029.
- The announcement follows stronger-than-expected Q2 earnings, 5% sales growth and raised full-year guidance.
GSK unveiled plans to relocate its UK research and development operations from Stevenage to a new flagship campus in Cambridge as part of a three-year restructuring programme aimed at delivering £1.9 billion in annual cost savings by 2029. The pharmaceutical giant will also invest £400 million in the new Cambridge R&D centre, consolidating its UK research teams to improve efficiency and accelerate the development of late-stage medicines.
The announcement comes a day after GSK reported stronger-than-expected second-quarter results, with sales rising 5%, core operating profit increasing 7%, and earnings per share beating analyst estimates. The company also raised its full-year sales and operating profit guidance, underscoring confidence in its growth outlook. Investors are now turning their attention from the earnings beat to GSK’s long-term restructuring strategy and how the cost-saving programme will support future profitability.
Why Is GSK Moving Its Stevenage R&D Operations to Cambridge?
GSK said the move is designed to streamline its UK research operations by bringing scientists together at a new Cambridge innovation hub. The company believes the investment will improve collaboration, increase operational efficiency and speed up the development of new medicines.
The relocation forms part of a broader transformation strategy that aims to generate £1.9 billion in recurring annual savings by 2029, while strengthening GSK’s pipeline of specialty medicines and vaccines.
GSK Raises Guidance After Strong Q2 Earnings
GSK reported second-quarter sales of £8.41 billion, up 5% year over year, driven by continued growth in specialty medicines and vaccines. Core operating profit rose 7%, while core earnings per share increased 9%.
The company also exceeded Wall Street expectations, reporting adjusted earnings of $0.6764 per share on revenue of $11.15 billion. Following the results, GSK raised its full-year sales and operating profit guidance toward the upper end of its previous forecast range, although EPS guidance remains in the lower half due to higher financing costs associated with the Nuvalent acquisition.
What Does the £1.9 Billion Savings Plan Mean for GSK?
The cost-saving programme is expected to reshape GSK’s operations over the next three years, with management targeting £1.9 billion in annual savings by 2029. The company plans to reinvest part of those savings into research and development, supporting innovation and expanding its late-stage drug pipeline.
The restructuring reflects GSK’s strategy of combining stronger financial performance with operational efficiencies as it positions the business for long-term growth.
GSK Share Price Outlook
GSK shares remained near 2,000 GBX after the earnings release, with investors balancing the company’s stronger financial performance against the impact of its long-term restructuring plans. The combination of higher sales, improved profitability, increased guidance and a significant cost-savings programme is expected to remain the key focus for investors as GSK continues executing its growth strategy.
GSK is relocating its UK research operations to Cambridge as part of a restructuring programme designed to improve efficiency, accelerate drug development and deliver £1.9 billion in annual cost savings by 2029.
Yes. GSK reported stronger-than-expected second-quarter earnings, with 5% sales growth, higher operating profit and raised full-year sales and operating profit guidance.
GSK plans to invest £400 million in the new Cambridge research and development campus as it consolidates its UK R&D operations.
